The promise for precision medicine in oncology continues to grow as researchers and clinicians discover more molecular pathways involved in the transformation of normal cells to cancerous ones. Critical to that promise is diagnostic testing that identifies which pathways are involved at an individual patient level. Such diagnostic information is used by doctors to inform a patient's prognosis or predict whether a particular treatment will be beneficial. In addition to the clear clinical advantages of bringing the right treatments to the right patients, diagnostic tests can prevent the tremendous economic waste of administering costly therapies to those who will not benefit from them.
While a few therapeutic and companion diagnostic pairings have been brought to market, many stakeholders fear that the current investment levels, regulatory standards, and reimbursement frameworks for cancer diagnostics are inadequate to carry the positive momentum forward and deliver on the promise of truly individualized care. Some believe greater evidence is needed to justify the investments being sought, and the question remains on how to support continuous innovation in oncology treatments.
Tapestry Networks has convened the multi-stakeholder Sustainable Predictive Oncology Therapeutics and Diagnostics (SPOT/Dx) Working Group to address this challenge.
Charting a course for the future
On July 15-16, 2014, the SPOT/Dx working group convened its third meeting in Arlington, Virginia. The group reaffirmed its commitment to cancer patients, outlined a pilot focused on enhancing the quality of future molecular diagnostics, continued to explore the merits of facilitated drug access/outcomes registry programs, and considered what future contribution the SPOT/Dx group could make to accelerate and safeguard the implementation of precision medicine in oncology.
Progress in precision medicine
Precision medicine promises to change the way we diagnose and care for cancer patients. However, the health system, including providers, infrastructure, reimbursement, and care delivery models, is not currently set up to optimize individualized care. The SPOT/Dx Working Group will be addressing the challenges associated with creating a sustainable model for predictive oncology therapeutics and diagnostics.
Precision medicine in oncology: a promise worth keeping
Tapestry Networks has convened the multi-stakeholder Sustainable Predictive Oncology Therapeutics and Diagnostics Working Group (SPOT/Dx WG) to address these challenges and consider new approaches to advance precision medicine in oncology. The group brings together key thought leaders and decision makers from the public and private sectors, including clinical and policy experts, regulators, third-party payers, patient advocates, and industry leaders. Working together through 2014, participants are committed to improving patient outcomes by equipping healthcare leaders with the tools to advance the diagnosis and treatment of cancer, clinical decision-making, and the regulatory/reimbursement infrastructure required to support a sustainable shift toward precision medicine.